Kairos Pharma Ltd. (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2 trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The analysis revealed a statistically significant difference in progression-free survival (PFS), with a median PFS of 17.7 months for patients receiving ENV-105 plus apalutamide compared to two months for those receiving apalutamide alone (P=0.0008). This marked improvement suggests that ENV-105, an antibody targeting CD105, may effectively reverse drug resistance and restore the effectiveness of standard therapies.
In response to these findings, Kairos Pharma has modified the Phase 2 protocol to enroll patients earlier in disease progression. Patients who experience a PSA increase following upfront treatment with an androgen signaling inhibitor will now be randomized to receive either enzalutamide alone or enzalutamide in combination with ENV-105. According to the company, this change is intended to expand the eligible patient population and facilitate enrollment, with completion of the Phase 2 trial targeted in or before the fourth quarter of 2027. The full press release can be accessed at https://ibn.fm/EDpxx.
Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. For the latest news and updates relating to KAPA, visit the company's newsroom at https://ibn.fm/KAPA.
The significance of these interim results extends beyond Kairos Pharma. Prostate cancer remains a leading cause of cancer death among men, and metastatic castration-resistant prostate cancer is particularly challenging to treat due to resistance to conventional androgen deprivation therapies. The substantial PFS benefit observed with ENV-105 plus apalutamide could represent a new treatment paradigm for patients who have become resistant to standard therapies. If the Phase 2 trial continues to demonstrate such efficacy, ENV-105 could become a valuable addition to the treatment landscape, potentially improving outcomes for a large patient population.
For investors, the positive interim data and protocol amendment signal progress in Kairos Pharma's clinical development program. The company's focus on addressing drug resistance through CD105 targeting differentiates it in the competitive oncology space. The announcement was disseminated through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution to millions of followers.
As the trial progresses, the medical community and investors will be watching closely for further updates on ENV-105's potential to address unmet needs in prostate cancer treatment. The modified protocol may accelerate enrollment and provide more robust data to support future regulatory submissions. For more information about BioMedWire and its services, visit https://www.BioMedWire.com. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
